Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises on listing of Opus Prodox AB (publ)
Mandate

Vinge advises on listing of Opus Prodox AB (publ)

March 27, 2012

Opus is a company which develops, produces and sells products relating to automotive test equipment, vehicle inspection systems and fleet management for the global market.

Opus has retained Vinge as its legal adviser in relation to the listing. The listing process has commenced in order for the company to be included on the main list of NASDAQ OMX Stockholm in 2012.

Vinge’s team includes responsible partner Anders Strid, Anna Björk Larsson (capital markets), Ulf Käll and Anna Hofling (due diligence and tax) and Emma Kero Ljungberg (project manager for legal due diligence).

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026